Is Cumberland Pharmaceuticals, Inc. overvalued or undervalued?

As of 2 August 2016, the valuation grade for Cumberland Pharmaceuticals, Inc. has moved from expensive to risky. The company appears to be overvalued based on its financial metrics. Key ratios include a Price to Book Value of 3.04, an EV to EBITDA of 34.34, and a negative ROCE of -19.13%.
In comparison to its peers, Cumberland's valuation is notably higher, with a P/E ratio not applicable due to losses, while BeyondSpring, Inc. has a P/E of -15.46 and an EV to EBITDA of -15.21. Additionally, Regulus Therapeutics, Inc. shows a P/E of -11.95, indicating that Cumberland is not only underperforming but also carries a higher risk profile. Despite a strong year-to-date return of 65.82%, the underlying financials suggest that the stock is overvalued relative to its peers and market conditions.